ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

计划入组 120 人 · 首次发布于 2021 年 8 月 20 日

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

计划入组 549 人 · 首次发布于 2020 年 11 月 30 日

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

计划入组 12 人 · 首次发布于 2023 年 5 月 6 日

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Axl tyrosine kinase inhibitors (SuperGen)

c-Met tyrosine kinase inhibitors (cancer)

Exelixis, Inc.

United States

ALK-ABELLO, INC.

United States

ALK-Abelló A/S

Denmark

TRIANA Biomedicines' TRI-611 Receives FDA Fast Track Designation for ALK+ NSCLC Treatment

Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL

Tyrosine Kinase Inhibitors and Gene Therapies Show Promise for Wet AMD Treatment